The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
The US regulator granted 14 accelerated approvals in 2019, fewer than in the previous two years, and the sector remains slow at conversions.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.